European Union Pharmaceutical Standards and the Quality of Imported Medicines in Nigerian Markets

This study investigates how European Union pharmaceutical manufacturing and quality standards influence the quality, availability, and pricing of medicines imported into Nigerian markets, with focus on wholesale pharmaceutical distribution in Onitsha (South-East) and Lagos Island (South-West). The EU is a major source of pharmaceutical products distributed in Nigeria, and EU Good Manufacturing Practice (GMP) standards are recognised as benchmarks for product quality. However, the intersection between EU-origin pharmaceutical imports, counterfeit medicines, and NAFDAC regulatory enforcement in Nigerian markets remains a significant public health concern. This descriptive study draws on NAFDAC regulatory reports, WHO global surveillance data, and secondary literature on pharmaceutical markets in sub-Saharan Africa published between 2020 and 2024. Structured interviews with pharmacists, wholesale distributors, and health regulatory officers in Onitsha and Lagos markets are incorporated as primary data. The study examines how EU pharmaceutical standards are communicated to Nigerian importers, the incidence of substandard EU-origin products identified by NAFDAC, and the regulatory gaps that allow non-compliant products to enter the supply chain. Findings are intended to contribute to undergraduate discourse on European regulatory influence in global pharmaceutical value chains and its implications for public health in Nigeria. Keywords: EU pharmaceutical standards, medicine quality, NAFDAC, Onitsha, Nigerian pharmaceutical market.